Germantown, Maryland, and State College, Pennsylvania, Jan. 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences. The university-industry partnership will serve as a beacon for this field by investigating research opportunities that address challenges and research gaps facing the microbiome, w ...

Venlo, the Netherlands, Jan. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split. The repayment from existing cash reserves is expected to lead to an approximately 3% reduction in the number of issued shares (based on current share price). The terms of the syntheti ...

QIAGEN N.V. (QGEN) recently received FDA clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu for its integrated PCR-based clinical molecular testing systems NeuMoDx 96 and 288 in the United States. The Assay is designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the country. The latest development will significantly boost the company’s Molecular Diagnostics business.About QIAGEN’s PCR-Based Clinical Molecular Testing SystemsThe NeuM ...

Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023. Press release date/time: Tuesday, February 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date/time: Wednesday, February 7, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.  Three options for joining the conference call Register for call back connect ...

QIAGEN’s (QGEN) business is expected to get a boost from its expanded test menu and growth-driving strategic collaborations. However, overdependence on relationships with collaborative partners and foreign exchange headwinds are major downsides. The stock carries a Zacks Rank #3 (Hold) currently.QIAGEN’s long-term business strategy involves entering into strategic alliances as well as marketing and distribution arrangements with academic, corporate and other partners relating to the development, commerciali ...

Germantown, Maryland, and Venlo, the Netherlands, Jan. 08, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced the U.S. Food and Drug Administration (FDA) clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu for its integrated PCR-based clinical molecular testing systems NeuMoDx 96 and 288 in the United States. This assay is designed for direct detection of asymptomatic and symptomatic bacterial infections involving Chlamydia trachomatis (CT) and / or Nei ...

Venlo, the Netherlands, Jan. 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock split. QIAGEN has decided to implement the maximum $300 million value of the mandate given at the Annual General Meeting in June 2023, where shareholders gave virtually unanimous approval f ...

Venlo, the Netherlands, Muscat, Oman, and Riyadh, Saudi Arabia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a significant expansion of its business in the Middle East region, which includes three major developments:  In early 2024, QIAGEN will open its regional headquarters in Riyadh, Saudi Arabia, in order to further strengthen its commercial footprint in the region.It has signed a memorandum of understanding (MoU) with the Ministry of Health of Sau ...

Before I hand over to Roland I would also like to mention a change in our leadership team. After leading our molecular diagnostic business since 2020, Jean-Pascal Viola has been appointed Senior Vice President, Head of Corporate Strategy and Development. He remains a member of the Executive Committee. We here want to capitalize on Jean-Pascal's contribution to QIAGEN since 2007 and his proven track record in business development. After a rigorous selection process, we would like to welcome Fernando Beils as ...

At this time, I would like to introduce your host, John Gilardi, Vice President, Head of Corporate Communications and Investor Relations at QIAGEN. Please go ahead. Hello, everyone. First of all, I would also like to thank Thomas for his significant contributions over his long and impactful career at QIAGEN. I would now like to hand back to Thierry. Roland Sackers With that, I'd like to thank you for your attention, hand back to John and the operator for the Q&A session. Thank you. We'll take our next quest ...